Cargando…

Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong

BACKGROUND: Concerns regarding the autoimmune safety of COVID-19 vaccines may negatively impact vaccine uptake. We aimed to describe the incidence of autoimmune conditions following BNT162b2 and CoronaVac vaccination and compare these with age-standardized incidence rates in non-vaccinated individua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xue, Gao, Le, Tong, Xinning, Chan, Vivien K.Y., Chui, Celine S.L., Lai, Francisco T.T., Wong, Carlos K.H., Wan, Eric Y.F., Chan, Esther W.Y., Lau, Kui Kai, Lau, Chak Sing, Wong, Ian C.K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008125/ https://www.ncbi.nlm.nih.gov/pubmed/35461018 http://dx.doi.org/10.1016/j.jaut.2022.102830

Ejemplares similares

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)
por: Li, Xue, et al.
Publicado: (2023)

Safety of BNT162b2 or CoronaVac COVID-19 vaccines in patients with heart failure: A self-controlled case series study
por: Ye, Xuxiao, et al.
Publicado: (2022)

Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study
por: Peng, Kuan, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study
por: Kang, Wei, et al.
Publicado: (2022)

Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease
por: Ye, Xuxiao, et al.
Publicado: (2022)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case–control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
por: McMenamin, Martina E, et al.
Publicado: (2022)

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong
por: Mok, Chris Ka Pun, et al.
Publicado: (2021)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS‐CoV‐2 Infection Among Patients With Cardiovascular Disease
por: Ye, Xuxiao, et al.
Publicado: (2023)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
por: Cheng, Franco Wing Tak, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study
por: Chui, Celine Sze Ling, et al.
Publicado: (2022)

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study
por: Huang, Caige, et al.
Publicado: (2023)

Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
por: Leung, Daniel, et al.
Publicado: (2022)

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study
por: Mok, Chris Ka Pun, et al.
Publicado: (2023)

Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination
por: Oskay, T., et al.
Publicado: (2021)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
por: Tan, Cheng Siang, et al.
Publicado: (2022)

Cutaneous reactions after CoronaVac and BioNTech vaccines
por: Öner, Ümran, et al.
Publicado: (2022)

Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Evaluation and follow-up of antibody formation after CoronaVac vaccine
por: Çalişir, Büşra, et al.
Publicado: (2022)

Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
por: Phoksawat, Wisitsak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c4rrho758eo3boutt222qcsdms